CERO THERAPEUTICS HOLDINGS, INC. 8-K

What Happened
CERO Therapeutics Holdings, Inc. filed a Form 8-K (Feb 4, 2026) to disclose a poster presentation the company prepared for the Transplantation and Cellular Therapy Meetings beginning on February 4, 2026. The poster presentation is included with the 8-K as Exhibit 99.1. The company notes the poster is summary information, should be read in context of its SEC filings and public announcements, and that it is not obligated to update the poster after the filing date.

Key Details

• Presentation scheduled to begin February 4, 2026 at the Transplantation and Cellular Therapy Meetings.
• Poster presentation is filed as Exhibit 99.1 to the Current Report on Form 8-K.
• Filing states the poster contains summary information and disclaims any obligation to update it after the report date.

Why It Matters
This 8-K is a routine disclosure that a public scientific poster will be presented; it does not report financial results, executive changes, mergers, or other corporate actions. Investors who track CERO’s clinical or research progress should review Exhibit 99.1 for the scientific details and monitor the company’s filings or press releases for any further updates.